Clinical trial NCT06054113: Study of Blinatumomab Administration in Chinese Pediatric Participants With Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
Official title: An Open-label, Multicenter, Phase 2 Study to Evaluate Efficacy, Safety, and Pharmacokinetics (PK) of Blinatumomab in Chinese Pediatric Subjects With Relapsed or Refractory B Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
Conditions: B Precursor Acute Lymphoblastic Leukemia
Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia
Keywords: Relapsed/Refractory B precursor Acute Lymphoblastic Leukemia
R/R B-ALL
Blinatumomab
Lead sponsor: Amgen
Sponsor class: INDUSTRY
First posted: 2023-09-26
Enrollment: 18
Sex: ALL
Minimum age (years): 1
Maximum age (years): 204
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The primary objective of this study is to evaluate the efficacy of blinatumomab.


Eligibility criteria: Inclusion Criteria:

* Participant's parent or legally authorized representative has provided informed consent when the participant is legally too young to provide informed consent and the participant has provided written assent based on local regulations and/or guidelines prior to any study-specific activities/procedures being initiated
* Pediatric participants aged \> 1 month and \< 18 years at the time of informed consent
* Relapsed or/refractory precursor B-cell acute lymphoblastic leukemia (ALL) disease, defined as ≥5% bone marrow blasts with at least one of the following:
* Second or later bone marrow relapse;
* Any marrow relapse after allogeneic hematopoietic stem cell transplant (alloHSCT);
* Refractory to other treatments:
* For participants in first relapse: failure to achieve a complete remission (CR) following a full standard reinduction chemotherapy regimen
* For participants who have not achieved a first remission, failure to achieve remission following a full standard induction regimen
* Karnofsky performance status ≥ 50% for participants ≥ 16 years
* Lansky performance status ≥ 50% for participants \< 16 years

Exclusion Criteria:

- Evidence of current central nervous system (CNS) involvement by ALL. Participants with CNS disease at the time of relapse are eligible if CNS is successfully treated prior to enrollment.

Other Medical Conditions

* Clinically relevant CNS pathology requiring treatment (eg, unstable epilepsy).
* Isolated extramedullary (EM) disease.
* Active malignancy other than ALL.
* Burkitt's leukemia according to the World Health Organization (WHO) 2016 criteria.
* Abnormal renal or hepatic function at screening as defined below:
* Abnormal serum creatinine based on age/gender as described by Threshold Creatinine Values
* Direct bilirubin \> 1.5 mg/dl (25.6 μmol/L) at screening (unless related to Gilbert's or Meulengracht disease).
* Symptoms and/or clinical signs and/or radiological and/or sonographic signs that indicate an acute or uncontrolled chronic infection, any other concurrent disease or medical condition that could be exacerbated by the treatment or would seriously complicate compliance with the protocol.
* Known infection with human immunodeficiency virus (HIV) or chronic infection with hepatitis B virus (hepatitis B surface antigen \[HBsAg\] positive) or hepatitis C virus (HCV) (anti-HCV positive).
* Known hypersensitivity to blinatumomab or any of the products or components of the blinatumomab formulation.

Prior/Concomitant Therapy

* AlloHSCT within 12 weeks prior to start of protocol-specified therapy.
* Active acute or chronic Graft-versus-Host-Disease (GvHD) requiring systemic treatment with immunosuppressive medication.
* Radiotherapy within 2 weeks prior to start of protocol-specified therapy.
* Immunotherapy (eg, rituximab) within 4 weeks prior to start of protocol-specified therapy. Prior failed cluster of differentiation 19 (CD19) directed therapy such as prior blinatumomab or CD19 chimeric antigen receptor T cells (CAR T cell) will be allowed (with demonstrated continued CD19+ expression) if treatment ended \> 4 weeks prior to start of protocol-specified therapy.
* Cancer chemotherapy within 2 weeks before the start of protocol-specified therapy. With the exception of intrathecal chemotherapy and/or low dose maintenance therapy for example vinca alkaloids, mercaptopurine, methotrexate, or hydroxyurea or pre-phase chemotherapy and/or dexamethasone. Any low dose chemotherapy as stated above must be discontinued before starting pre-phase.

Prior/Concurrent Clinical Study Experience

- Currently receiving treatment in another investigational device or drug study, or less than 4 weeks since ending treatment on another investigational device or drug study(ies). Other investigational procedures while participating in this study are excluded.

Other Exclusions

* Female participants of childbearing potential with a positive pregnancy test assessed at Screening by a highly sensitive urine or serum pregnancy test.
* Female participants who are breastfeeding or who plan to breastfeed while on study through 12 months after the last dose of protocol-required treatment with highest teratogenic risk.
* Female participants of childbearing potential unwilling to use protocol-specified method of contraception during treatment and for an additional 12 months after the last dose of protocol-required treatment with highest teratogenic risk.
* Male participants with a female partner of childbearing potential who are unwilling to practice sexual abstinence (refrain from heterosexual intercourse) or use contraception during treatment and for an additional 6 months after the last dose of protocol-required therapy with highest teratogenic risk.
* Participant likely to not be available to complete all protocol-required study visits or procedures, and/or to comply with all required study procedures to the best of the participant and investigator's knowledge.
* Female participants planning to become pregnant while on study through 12 months after the last dose of protocol-required treatment with highest teratogenic risk.
* Male participants unwilling to abstain from donating sperm during treatment and for an additional 6 months after the last dose of protocol-required treatment with highest teratogenic risk.

Primary outcomes:
measure: Number of Participants with Complete Remission (CR)
timeFrame: Up to 84 days
measure: Number of Participants with CR with Partial Recovery of Peripheral Blood Counts (CRh)
timeFrame: Up to 84 days
Secondary outcomes:
measure: Number of Participants with Treatment-emergent Adverse Events (TEAEs)
timeFrame: Up to approximately 240 days
measure: Number of Participants with Serious TEAEs
timeFrame: Up to approximately 2 years
measure: Number of Participants with Treatment-related TEAEs
timeFrame: Up to approximately 240 days
measure: Number of Participants with Adverse Events of Interest
timeFrame: Up to approximately 240 days
measure: Steady State Concentration (Css) of Blinatumomab
timeFrame: Days 3, 8, 9 and 29
measure: Clearance of Blinatumomab
timeFrame: Days 3, 8, 9 and 29
measure: Overall Survival (OS) Rate
timeFrame: Up to approximately 2 years
measure: Relapse-Free Survival (RFS) Rate
timeFrame: Up to approximately 2 years
measure: Number of Participants who Receive Allogeneic Hematopoietic Stem Cell Transplant (alloHSCT)
timeFrame: Up to approximately 2 years
measure: 100-day Mortality Rate After alloHSCT
timeFrame: Up to approximately 2 years
measure: Number of Participants with Anti-blinatumomab Antibody (ADA) Formation
timeFrame: Up to approximately 240 days
measure: Minimal Residual Disease (MRD) Response
timeFrame: Up to 84 days
Other outcomes:
Locations:
city: Chongqing
country: China
facility: Childrens Hospital of Chongqing Medical University
state: Chongqing
city: Guangzhou
country: China
facility: Zhujiang Hospital of Southern Medical University
state: Guangdong
city: Suzhou
country: China
facility: Children's Hospital of Soochow University
state: Jiangsu
city: Shanghai
country: China
facility: Shanghai Children's Medical Center
state: Shanghai
city: Tianjin
country: China
facility: Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
state: Tianjin
Study officials:
affiliation: Amgen
name: MD
role: STUDY_DIRECTOR
References: